Disclosed herein is a T-helper cell (“T.sub.H-GM” cell) that is regulated by IL-7/STAT5 and which secrete GM-CSF/IL-3. Also disclosed are methods and compositions for modulating T.sub.H-GM function for the treatment of, e.g., inflammatory disorders. Diagnostic and prognostic methods for specifically identifying T.sub.H-GM-mediated inflammatory disorders (e.g., rheumatoid arthritis), as distinct from and/or in addition to non-T.sub.H-GM-mediated (e.g., TNF-α-mediated) inflammatory disorders, are also provided.

Methods and compositions are provided for translational profiling and molecular phenotyping of specific tissues, cells and cell subtypes of interest. The methods provided herein facilitate the analysis of gene expression in the selected subset present within a heterogeneous sample.

The present disclosure provides isolated polypeptides with vitamin D3 binding activity and methods for their use as detection agents. In another aspect, the invention provides recombinant expression vector comprising an isolated nucleic acid of the invention operably linked to a control sequence. In another aspect, the invention provides recombinant host cells comprising the recombinant expression vector of the invention. In another aspect, the invention provides methods for detecting vitamin D3 or one of its metabolites, such as 25-D3, comprising contacting a sample of interest with a detectable polypeptide of the invention.

The present invention relates to the screening, diagnosis, prognostic evaluation, and treatment or prevention of age associated inflammation, chronic inflammation, and inflammatory diseases. In particular, the present invention relates to treating or preventing inflammatory diseases (e.g. rheumatoid arthritis or spondyloarthritis) or patients with inflammatory peripheral GnRH with GnRH antagonists or drugs that lower the effects of GnRH.

The present disclosure provides compounds and methods useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

The invention provides epsilon toxin (ETX) produced by Clostridium perfringens type B or type D as a causative toxin for human multiple sclerosis (MS). The invention further identifies ETX binding receptor MAL for ETX mediated cell death and other toxin-logical activities in MS. Methods and compositions to prevent humans from multiple sclerosis (MS) and/or treating MS by directly or indirectly interfering with epsilon toxin (ETX), its binding receptor (e.g., MAL), or ETX-receptor interactions so as to inhibit or suppress downstream ETX mediated receptor signaling activities are provided. Also provided are various methods to detect, diagnose, monitor, assess multiple sclerosis (MS) by determining an expression level of ETX gene or its encoding protein in human patient suspected for and/or at risk for multiple sclerosis (MS).

A method for predicting or prognosticating the response of individuals with multiple sclerosis to treatment with IFNβ, kit or device, and uses.

Methods and compositions for detecting and/or measuring biomarkers associated with compromised BBB.

A method for evaluating a subject for a biological condition associated with metal metabolism includes sampling positions along a biological sample of the subject to obtain several ion samples. Each ion sample corresponds to a position on the biological sample and each position represents an amount of growth of the biological sample. The obtained ions are analyzed with a mass spectrometer thereby obtaining a plurality of traces. Each such trace represents a concentration of a corresponding elemental isotope, in a plurality of elemental isotopes, over time. A set of features is derived from the traces. Each feature is determined by a variation of a single isotope or a combination of isotopes in the plurality of traces. The set of features is inputted into a trained classifier to obtain a probability that the subject has the biological condition associated with metal metabolism.

Dosage regimens, methods, compositions and kits are described herein useful for detecting and/or treating a CNS demyelinating disease.